Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.
Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.
Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.
The company's product pipeline includes two promising therapies:
- SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
- SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.
Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.
Silence Therapeutics plc, a leader in siRNA therapeutics, announced preliminary results from the GEMINI II phase 1 study of SLN124 targeting the TMPRSS6 gene in adults with non-transfusion dependent thalassemia. The study showed an encouraging safety profile with no serious adverse events or dose limiting toxicities. Pharmacokinetic and pharmacodynamic evaluations are ongoing, with results expected next year. SLN124 has received FDA Fast Track Designation for polycythemia vera, and a phase 1/2 trial is planned for later this year, showcasing its potential across various hematological conditions.
Silence Therapeutics plc (Nasdaq: SLN) announced that Giles Campion, MD, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 4 at 3:45 p.m. ET in New York. The event can be viewed live on the company's website. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet medical needs, leveraging its mRNAi GOLD™ platform. Major products include SLN360 for cardiovascular risk and SLN124 for rare hematological diseases. Collaborations with AstraZeneca and others enhance their research efforts.
Silence Therapeutics, a leader in RNAi therapeutics, announced participation in two upcoming conferences in New York. The first is the Morgan Stanley Global Healthcare Conference, featuring a fireside chat on September 13, 2022, at 5:15 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, with a fireside chat on September 14, 2022, at 4:00 p.m. ET. Investors can access webcasts of these chats on the company’s website. Silence focuses on developing siRNA therapeutics targeting diseases with significant unmet needs.
Silence Therapeutics has received Fast Track Designation from the FDA for SLN124, an siRNA targeting the TMPRSS6 gene, aimed at treating polycythemia vera (PV). This designation could accelerate the development and review process, enabling quicker patient access to treatments. SLN124 has shown proof of mechanism and tolerability in prior studies. The company also plans to initiate a phase 1/2 study this year and is evaluating SLN124 for other hematological diseases.
Silence Therapeutics plc (NASDAQ: SLN) announced pricing for an underwritten offering of 5,950,000 American Depositary Shares (ADSs) at $9.50 each, yielding approximately $56.5 million before expenses. The offering aims to fund clinical trials, including Phase 2 SLN360 for ASCVD and Phase 1/2 SLN124 for polycythemia vera. The offering is expected to close around August 16, 2022. Morgan Stanley and William Blair are joint book-running managers. Silence's focus is on RNA interference therapeutics targeting significant unmet medical needs.
Silence Therapeutics plc, a leader in siRNA therapeutics, announced its participation in the Jefferies Healthcare Conference on June 9, 2022, at 10:00 a.m. EDT / 2:00 p.m. GMT. The presentation will be accessible via a live webcast on the company’s website, with an archived replay available afterward. Silence is focused on RNA interference technology to develop treatments for diseases, with key products including SLN360 for cardiovascular risk and SLN124 for hematological disorders. The company collaborates with AstraZeneca and others.
Silence Therapeutics plc (NASDAQ: SLN) announced its participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The on-demand presentation will be available on May 23 at 7:00 AM ET via the Silence website. Silence specializes in RNA interference (RNAi) therapeutics targeting significant unmet medical needs. Key candidates include SLN360 for cardiovascular risk reduction and SLN124 for hematological diseases. The Company collaborates with AstraZeneca and others to advance its innovative therapies.
Silence Therapeutics plc (NASDAQ: SLN) reported its Q1 2022 financial results, highlighting progress in its development pipeline. Key achievements include positive SLN360 data presented at ACC and FDA orphan drug designation for SLN124. Financially, the company generated £5.7 million in revenue, up from £3.1 million in Q1 2021, while net loss decreased to £7.7 million from £8.4 million. As of March 31, 2022, cash and equivalents totaled £59.3 million. The company anticipates further milestones, including durability data for SLN360 and topline results for SLN124, both expected in Q3 2022.
Silence Therapeutics plc (Nasdaq: SLN) announced a $2.0 million cash payment from Hansoh Pharmaceutical Group, following the achievement of a preclinical milestone in their collaboration established in October 2021. This deal involves developing siRNAs utilizing Silence’s mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to two targets outside China, while Hansoh holds rights in China. Silence also stands to gain up to $1.3 billion in additional milestones and royalties from Hansoh's net product sales.
Silence Therapeutics, listed on Nasdaq as SLN, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. Eastern Time. The presentation will focus on the company's innovative siRNA therapeutics aimed at treating unmet medical needs, including cardiovascular risks and rare hematological diseases. A live webcast will be available on the company’s website, followed by a replay. Silence leverages its proprietary mRNAi GOLD™ platform and collaborates with major industry players.
FAQ
What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?
What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?
What is Silence Therapeutics Plc?
What is RNA interference (RNAi)?
What is SLN360 therapy?
What is SLN124 therapy?
How does Silence Therapeutics target specific cells?
What diseases are Silence Therapeutics' therapies targeting?
How does SLN360 reduce cardiovascular risks?
What is the role of hepcidin in SLN124 therapy?
Where can I find more information about Silence Therapeutics' projects?
What makes Silence Therapeutics unique?
